Simulations Plus (NASDAQ:SLP) Issues Earnings Results, Misses Expectations By $0.01 EPS

Simulations Plus (NASDAQ:SLP) posted its earnings results on Tuesday. The technology company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01), Zacks reports. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%.

Simulations Plus Trading Up 4.4 %

Shares of NASDAQ SLP traded up $1.29 on Tuesday, reaching $30.39. 457,671 shares of the company traded hands, compared to its average volume of 274,444. The stock has a market capitalization of $610.38 million, a PE ratio of 62.02 and a beta of 0.80. Simulations Plus has a fifty-two week low of $27.07 and a fifty-two week high of $51.22. The company has a 50 day moving average of $29.78 and a 200 day moving average of $34.16.

Analyst Ratings Changes

SLP has been the topic of a number of recent research reports. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, November 6th. BTIG Research reduced their price objective on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Stephens initiated coverage on shares of Simulations Plus in a research note on Friday, November 15th. They issued an “overweight” rating and a $39.00 target price for the company. Finally, StockNews.com lowered shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Simulations Plus presently has an average rating of “Moderate Buy” and a consensus target price of $51.40.

Insider Buying and Selling

In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $31.76, for a total value of $635,200.00. Following the transaction, the director now directly owns 3,442,584 shares of the company’s stock, valued at $109,336,467.84. The trade was a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 19.40% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.